Doniesienia naukowe
Wielkość czcionki: A | A | A

European commission gives enzalutamide marketing authorisation for advanced prostate cancer data: 2013-07-12

Tagi: Enzalutamide, Astellas, Xtandi

Enzalutamide has been authorised in European Union (EU) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

czytaj więcejnext
Full genomic analysis of clear-cell renal cell carcinoma leads way for targeted therapies data: 2013-07-12

Tagi: clear cell renal cell carcinoma, ccRCC

Approximately 2-3% of all cancers in adults occur in the kidney; there are several forms of kidney cancer, and the most prevalent of these is clear cell renal cell carcinoma (ccRCC) accounting for 70-80% of all cases.

There will therefore be approximately 189,000-217,000 new cases of this disease diagnosed worldwide each year.

The molecular mechanisms that lead to the development of this tumour are not yet completely understood, and complete cures only occur if the whole of the tumour can be removed with surgery.

czytaj więcejnext
NHS to offer preventative tamoxifen or raloxifene to women at high risk of breast cancer data: 2013-07-11

Tagi: Breast cancer, tamoxifen, raloxifene, NICE

Women at risk of breast cancer due to their family history now have more options than ever before to help prevent the disease, following updated guidance from NICE.

czytaj więcejnext
New understanding of why anti-cancer therapy stops working at a specific stage data: 2013-07-11

Tagi: Protein mTOR, mTOR inhibitors, Rapamycin,

Researchers at the Hebrew University of Jerusalem and in California have achieved a breakthrough in understanding how and why a promising anti-cancer therapy has failed to achieve hoped-for success in killing tumour cells. 

Their work could lead to new insights into overcoming this impasse.

The problematic therapy investigated involves suppression of the protein mTOR (mammalian target Of Rapamycin).

czytaj więcejnext
Researchers aim to target achilles' heel of moving cancer cells data: 2013-07-11

Tagi: Cancer cells, cancer spread,

Cancer Research UK scientists are shedding new light on cancer spread – which could help in the development of new treatments for patients according to a study published inNature Cell Biology.

The ability to spread is one of the most deadly properties of cancer cells.

Their tendency to move from the original tumour site and colonise other parts of the body causes the greatest number of deaths from cancer.

Scientists at the Cancer Research UK London Research Institute are looking at different types of cancer cell movement in order to help develop drugs that could prevent the disease from spreading.

czytaj więcejnext
Cure for young acute myeloid leukaemia patients increases six-fold since 1970s data: 2013-07-11

Tagi: Acute myeloid leukaemia (AML)

Almost half of teens and young adults with acute myeloid leukaemia (AML) – a typically aggressive form of leukaemia – are cured thanks to improvements in treatment and care, according to research published in the British Journal of Haematology.

The research, led by the London School of Hygiene & Tropical Medicine and co-funded by Cancer Research UK  and the Laura Crane Youth Cancer Trust, estimates the ‘cure rate’ for 15-24 year olds diagnosed in 2006 at 48 percent – six times the rate in 1975, which was then just eight per cent.

Similarly large improvements are estimated for older patients, right through to those in their 50s. But older patients today still have poor survival – only 13 per cent of patients diagnosed in 2006 aged 60-69 are predicted to be cured, and this drops to less than five per cent of those aged 70 and over.

czytaj więcejnext
Oral anti-cancer therapy, lenalidomide, now indicated as a treatment for patients with rare blood disease data: 2013-07-10

Tagi: lenalidomide, Celgene, myelodysplastic syndromes, MDS

Celgene International Sàrl was notified that the European Commission (EC) has amended the marketing authorisation for lenalidomide.

This decision means that lenalidomide is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

czytaj więcejnext
Men's risk of oesophageal cancer is triple women's risk data: 2013-07-10

Tagi: oesophageal cancer, adenocarcinoma

Men are almost three times more likely to get oesophageal cancer than women – one of the biggest gender gaps in cancer rates  –  according to figures released from Cancer Research UK.

czytaj więcejnext
Abnormalities in new molecular pathway may increase breast cancer risk data: 2013-07-10

Tagi: breast cancer, gene ZNF365,

A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

czytaj więcejnext
Genetic variations may help identify best candidates for preventive breast cancer drugs data: 2013-07-10

Tagi: breast cancer, selective oestrogen receptor modulator drugs, tamoxifen, raloxifene

Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective oestrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found.

czytaj więcejnext
prev 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | next
  • login
  • login
  • login
  • login
  • login
  • login
  • login
  • login
  • login
  • login
Data aktualizacji strony: 2016-03-09

Informujmy, że portal, korzysta z plików cookie (ciasteczka). Aby uzyskać więcej informacji o ich wykorzystywaniu,
przejdź do Polityki Prywatności. Kliknij "akceptuję" aby to okno nie pokazywało się więcej